Glutathione protection against gentamicin ototoxicity depends on nutritional status.
This study demonstrates that gentamicin ototoxicity depends on dietary factors and correlates with tissue glutathione levels. After 15 days of gentamicin injections (100 mg/kg/day s.c.) guinea pigs on a regular protein diet (18.5% protein) had an average hearing loss of 9 dB at 3 kHz, 31 dB at 8 kHz and 42 dB at 18 kHz. Guinea pigs on a 7% protein diet showed an increased hearing loss of 52 dB at 3 kHz, 63 dB at 8 kHz and 74 dB at 18 kHz. Supplementing the low protein diet with either essential or sulfur-containing amino acids did not protect against gentamicin ototoxicity. Glutathione levels in the cochlear sensory epithelium were decreased in animals on a low protein diet and could be restored to normal by oral administration of glutathione monoethyl ester (1.2 g/kg/day) in combination with vitamin C (100 mg/kg/day). Glutathione supplementation significantly reduced the magnitude of hearing loss in the low protein diet group at all frequencies (43 dB reduction at 3 kHz, 27 dB reduction at 8 kHz and 21 dB reduction at 18 kHz). In animals on a full protein diet, dietary glutathione neither increased cochlear glutathione levels nor attenuated hearing loss. Serum gentamicin levels did not differ between animals on the various diets with or without glutathione supplement. These results suggest that gentamicin toxicity and detoxifying mechanisms are affected by the metabolic state of the animal and the glutathione content of the tissue. Thus, compounds that could potentially protect against gentamicin ototoxicity may be more correctly assessed in animal models of deficient nutritional states in which endogenous detoxifying mechanisms are compromised. This animal model might also be more realistically related to the clinical situation of a critically ill patient receiving gentamicin treatment.
Lautermann
J
J
Kresge Hearing Research Institute, Department of Otolaryngology, University of Michigan, Ann Arbor 48109-0506, USA.
McLaren
J
J
Schacht
J
J
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000633:toxicity*; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D003051:Cochlea / Q000187:drug effects / Q000378:metabolism; D004032:Diet / Q000592:standards*; D004044:Dietary Proteins / Q000008:administration & dosage; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects / Q000502:physiology; D005527:Food, Fortified; D005839:Gentamicins / Q000008:administration & dosage / Q000097:blood / Q000633:toxicity*; D005978:Glutathione / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D006168:Guinea Pigs; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control; D007279:Injections, Subcutaneous; D008297:Male; D009752:Nutritional Status; D013702:Temporal Lobe / Q000187:drug effects / Q000473:pathology; D014722:Vestibule, Labyrinth / Q000187:drug effects / Q000473:pathology; D015430:Weight Gain / Q000187:drug effects
D000900:Anti-Bacterial Agents; D004044:Dietary Proteins; D005839:Gentamicins; D005978:Glutathione; D001205:Ascorbic Acid